Search

Your search keyword '"Aitchison M"' showing total 218 results
Start Over Author "Aitchison M"
218 results on '"Aitchison M"'

2. NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy

Author

Neves, J.B, primary, Warren, H., additional, Santiapillai, J., additional, Rode, N., additional, Cullen, D., additional, Pavlou, M., additional, Walkden, M., additional, Patki, P., additional, Barod, R., additional, Mumtaz, F., additional, Aitchison, M., additional, Bandula, S., additional, Pizzo, E., additional, Ranieri, V., additional, Williams, N., additional, Wildgoose, W., additional, Gurusamy, K., additional, Emberton, M., additional, Bex, A., additional, and Tran, M.G.B., additional

Published
2023
Full Text
View/download PDF

4. P143 - NEphron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot assisted partial nephrectomy

Author

Neves, J.B, Warren, H., Santiapillai, J., Rode, N., Cullen, D., Pavlou, M., Walkden, M., Patki, P., Barod, R., Mumtaz, F., Aitchison, M., Bandula, S., Pizzo, E., Ranieri, V., Williams, N., Wildgoose, W., Gurusamy, K., Emberton, M., Bex, A., and Tran, M.G.B.

Published
2023
Full Text
View/download PDF

6. Abstracts

Author

Rosen, L., Reed, J., Ufberg, D., Thorburn, H., Carter, K., Goldberg, J., Finlay, I. G., Church, J. M., Hill, G. L., Carter, F. M., Cohen, Z., McLeod, R. S., Bauer, J. J., Sher, M. E., Gelernt, I. M., Crim, R. W., Fazio, V. W., Lavery, I. C., Williams, J. G., Nemer, F. D., Rothenberger, D. A., Goldberg, S. M., Hyman, N. H., Tuckson, W. B., Deutsch, A. A., Gregoire, R., Cullen, J., Johnson, G. P., Wolff, B. G., Koltun, W., Schoetz, Jr., D. J., Roberts, P. L., Murray, J. J., Coller, J. A., Veidenheimer, M. C., Keighley, M. R. B., Hosie, K., Sakaguchi, M., Tudor, R., Kmiot, W., Ambroze, Jr., W. L., Dozois, R. R., Pemberton, J. H., Kelly, K. A., Wiltz, O., Hashmi, H., Fucini, C., Thayer, M. L., Madoff, R. D., Jacobs, D. M., Bubrick, M. P., Galandiuk, S., Tsao, J., Ilstrup, D. M., Duthie, G. S., Bartolo, D. C. C., Miller, R., Pinho, M., Kunin, J. D., Fleshman, J. W., Kodner, I. J., Fry, R. D., Wexner, S. D., Jagelman, D. G., Corredor, C., Salanga, V., Scholefield, J. H., Whatrup, C., Talbot, I. C., Northover, J. M. A., Sonnex, C., Safavi, A., Gottesman, L., Dailey, T., Moenning, S., Nightengale, S., Simonton, T., Huber, P., Odom, C., Kaplan, E., Strong, S. A., Milsom, J. W., Taylor, C. W., Cho, C. C., Stewart, W. R. C., Hartmann, R. F., Khanduja, K. S., Aguilar, P. S., Rahman, S. M., Arnold, M. W., Caushaj, P., Viratyosin, S., French, T., Madoff, R., Karamjit, S., Meesig, D. M., Macleod, C. A. H., Balcos, E. G., Buls, J. G., Nelson, H., Donohue, J. H., McKean, D. J., Leu, S. Y., Wang, S. R., Hsu, H., Ramanujam, P. S., Alberts, D. S., Clark, L., Ritenbaugh, C., Rowley, S., Kane, N., Jones, C., Davies, A., Baker, P., Neoptolemos, J. P., Devereux, D. F., Robertson, F. M., Spain, D. A., Cance, W. G., Cohen, A. M., Sigurdson, E. R., Enker, W. E., Konishi, F., Yasuda, Y., Ochiai, S., Kanazawa, K., Davis, M., Medina, V., Miller, D., Fielding, L. P., Prats, I., Berman, M., West, B., Savoca, P. E., Ballantyne, G. H., Flannery, J. T., Modlin, I. M., Tsukada, K., Jagelman, D. A., McGannon, E. M., Schroeder, T., Sakamoto, G. D., MacKeigan, J. M., Opelka, F., Timmcke, A., Gathright, J. B., Hicks, T., Ray, J., McKee, C. C., Ragland, J. J., Myers, J. O., Christie, J. P., Marrazzo, III, J., Flemming, F. X., Longo, W. E., Pollard, C. W., Nivatvongs, S., Rojanasakul, A., Jetmore, A. B., Baker, J., Wiltz, O. H., McKee, R. F., Lauder, J., Poon, F., Aitchison, M., Fleshman, James W., Dreznik, Zeev, Kodner, Ira J., Fry, Robert D., Kerner, B. A., Labow, S., Hoexter, B., Moseson, M., Cheape, J. D., Bowinkelman, K., Dziki, A. J., Malthaner, R. A., Harmon, J. W., Saini, N., Duncan, M. D., Fernicola, M. T., Fischer, B. A., Hakki, F. Z., Trad, K. S., Ugarte, R., Senagore, A. J., Mazier, W. P., Kilbride, M., Herrera, L., Goumas, W., Petrelli, N., Bailey, H. R., Huval, W. V., Max, E., Smith, K. W., Marks, G., Mohiuddin, M., Basile, M., Eitan, A., Wolff, B., Dozois, R., Devine, R., Beart, R., Kelly, A., Unti, J. A., Orsay, C. P., Pearl, R. K., Nelson, R. L., Duarte, B., Prasad, M. L., Abcarian, H., Senagore, A., Milson, J. W., Strong, S., Walshaw, R. K., Chaudry, I. H., Hojo, K., Sugihara, K., Katunuma, K., Vernava, A., Beart, R. W., Stewart, J., Diament, R. H., Salter, M., Brennan, T. G., Sheikh, F., Khubchandani, I. T., Miyajima, N., Uematsu, Y., Kodaira, S., Teramoto, T., Orrom, W. J., Duthie, G., Corne, H., Blatchford, G. J., Perry, R. E., Christensen, M. A., Thorson, A. G., Dreznik, Zeev, Wong, W. D., Jensen, L. L., Lee, K. H., Yoon, Choong, Joo, H. Z., Levien, D. H., Gibbons, S., Begos, D., Byrne, D. W., Gordon, P. H., Bégin, L. R., Mitmaker, B., Saclarides, T., Bhattacharyya, A., Britton, C., Stone, J. M., Lowry, A. C., Moran, M., Launer, D. P., McReynolds, D. G., Eastman, A. B., Peck, J. J., Rozycki, G. S., Ramanujam, Paravasthu S., Bellapravalu, Sharad, Venkatesh, Kurakurachi S., Griffin, Kathleen M., Vernava, A. M., Beckman, R., Andrus, C., Johnson, F., Herrmann, V., Kaminski, D. L., Wetter, L. A., Dinneen, M., Levitt, M., Motson, R. W., Rohrer, D. A., Bapna, M. S., Rotstein, L. E., Radhakrishnan, Jayant, Shrader, Charisse, Ravo, B., Frattaroli, F. M., Reggio, D., Litchy, W. J., Hanson, R. B., Morgado, Pedro J., Alfaro, Rodrigo, Alfonzo, Rafael, Vachon, D. A., Oliver, G. C., Eisenstat, T. E., Salvati, E. P., Rubin, R. J., Clay, R. P., Kumar, Sanath, Guillem, J. G., Levy, M. F., Hsieh, L. L., Johnson, M. D., Forde, K. A., Weinstein, I. B., Bilchik, A. J., Fleming, F. X., Pernikoff, B. J., Goldenring, J. R., Fozard, J. B., Lowndes, R. H., Young, H. L., Sackier, J., Leite, J. F. M. S., Fausto-Pontes, Martins, M. I., Kmiot, W. A., Youngs, D. J., Harding, L. K., Hesselwood, S. R., Smith, N., Hartley, M. G., Hudson, M. J., Hill, M. J., Gent, A. E., Grace, R. H., Swarbrick, E. T., Hellier, M. D., Procaccino, J. A., Oakley, J. R., Flanagan, Jr., R. A., Lapos, L., Riether, R. D., Stasik, J. J., Trostle, D. R., Sheets, J. A., Ferrara, A., Armstrong, D. N., Bjorck, S., McMillen, M. A., Nicholson, J. D., Halleran, D. R., Trivisonno, D. P., Ziegler, J. A., Lott, J., Saleeby, R., Sullivan, T., and Nelson, R.

Published
1990
Full Text
View/download PDF

14. Discrete-choice experiment to analyse preferences for centralizing specialist cancer surgery services

Author

Vallejo-Torres, L, primary, Melnychuk, M, additional, Vindrola-Padros, C, additional, Aitchison, M, additional, Clarke, C S, additional, Fulop, N J, additional, Hines, J, additional, Levermore, C, additional, Maddineni, S B, additional, Perry, C, additional, Pritchard-Jones, K, additional, Ramsay, A I G, additional, Shackley, D C, additional, and Morris, S, additional

Published
2018
Full Text
View/download PDF

15. Routine renal mass biopsy in diagnosis of renal cancer

Author

Tanabalan, C., primary, Neves, J., additional, Patki, P., additional, Mumtaz, F., additional, Ramachandran, N., additional, Grant, L., additional, Walkden, M., additional, Aitchison, M., additional, Tran, M., additional, and Barod, R., additional

Published
2018
Full Text
View/download PDF

19. Perineal excision of the rectum for prolapse in the elderly

Author

Finlay, I.G. and Aitchison, M.

Subjects
Proctology -- Methods, Rectum -- Prolapse, Perineum, Health
Abstract

Complete rectal prolapse (protrusion of the rectal mucosa through the anus) is a serious problem of elderly women. Because this condition may require placing the patient in a nursing home, surgery should be considered even for frail patients. The ideal surgery would be minimally invasive, correct the abnormality, and restore anorectal function. A surgical approach through the perineum (area between the vulva and anus) is less invasive and less dangerous than an abdominal rectopexy (fixation of the rectum through abdominal incision). A report is presented of 17 elderly women who underwent perineal excision of the rectum for prolapse. There was one postoperative death due to a heart attack, and another patient had recurrence of the prolapse in the immediate postoperative period. The average follow-up was 24 months, at which time eight patients had regained total continence, five had slight leakage that did not interfere with their daily activities, and three patients were severely incontinent. These results compare favorably with the results following rectopexy. It is concluded that this procedure offers a less invasive alternative to abdominal rectopexy and may be the procedure of choice for the majority of patients with complete rectal prolapse. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

25. Prostate cancer unit initiative in europe: a consensus on standards of care

Author

Valdagni, R., primary, Van Poppel, H., additional, Aitchison, M., additional, Albers, P., additional, Berthold, D., additional, Bossi, A., additional, Brausi, M., additional, Denis, L., additional, Drudge-Coates, L., additional, Feick, G., additional, Hoyer, M., additional, Hummel, H., additional, Mirone, V., additional, Müller, S.C., additional, Parker, C., additional, Sternberg, C.N., additional, Tombal, B., additional, van Muilekom, E., additional, Watson, M., additional, Wesselmann, S., additional, and Costa, A., additional

Published
2015
Full Text
View/download PDF

27. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer

Author

Lamb, G.W., McArdle, P.A., Ramsey, S., McNichol, A.M., Edwards, J., Aitchison, M., and McMillan, D.C.

Subjects
RC0254, RD
Abstract

To examine the relationship between the systemic inflammatory response (C-reactive protein, CRP), tumour interleukin-6 receptor and cyclooxygenase (COX)-2 expression, tumour T-lymphocytic (CD4+, CD8+) infiltration and cancer survival in patients undergoing resection for renal cell carcinoma (RCC), as both the local and systemic inflammatory responses appear to predict the outcome in these patients.\ud PATIENTS AND METHODS:\ud \ud The study included 60 patients undergoing nephrectomy for localized RCC. Pre-operative circulating CRP levels were measured and tumour interleukin-6 receptor and COX-2 expression, tumour CD4+ and CD8+ T lymphocytes were assessed using immunohistochemical analysis.\ud RESULTS:\ud \ud The median follow-up was 78 months, with 14 patients relapsing from their disease and nine cancer-specific deaths. On univariate and multivariate survival analysis, tumour stage and grade and CRP levels were identified as significant factors associated with relapse-free and cancer-specific survival. There was a significant direct relationship between Fuhrman grade and CD4+ T-lymphocytic infiltrate (P > 0.05). An increase in tumour expression of interleukin-6 receptor was weakly associated with an increase in tumour CD8+ T-lymphocytic infiltration (P = 0.057). An increase in tumour CD4+ T-lymphocytic infiltration was associated with an increase in CD8+ T-lymphocytic infiltration (P > 0.01).\ud CONCLUSIONS:\ud \ud The present results suggest that tumour-based factors such as interleukin-6 receptor and COX-2 expression or T-lymphocytic subset infiltration are subordinate to systemic factors such as CRP level in determining survival in patients with localized RCC.

Published
2008

28. 197 The effect of anti-VEGF tyrosine kinase inhibitors on biomarkers and tumour heterogeneity in metastatic clear cell renal cancer

Author

Stewart, G.D., primary, Laird, A., additional, O'Mahony, F.C., additional, Eory, L., additional, Lubbock, A.L.R., additional, Nanda, J., additional, O'Donnell, M., additional, Mackay, A., additional, Mullen, P., additional, McNeill, S.A., additional, Riddick, A.C.P., additional, Peters, J., additional, Patki, P., additional, Aitchison, M., additional, Berney, D., additional, Bex, A., additional, Overton, I.M., additional, Harrison, D.J., additional, and Powles, T., additional

Published
2014
Full Text
View/download PDF

29. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial

Author

Aitchison, M., primary, Bray, C.A., additional, Van Poppel, H., additional, Sylvester, R., additional, Graham, J., additional, Innes, C., additional, McMahon, L., additional, and Vasey, P.A., additional

Published
2014
Full Text
View/download PDF

30. Towards optimizing thermal performance of prefabricated houses in Australian climates.

Author

Soret, G. M., Tonino, J., Torero, J. L., and Aitchison, M.

Subjects
PREFABRICATED buildings, THERMAL properties of buildings, SUSTAINABILITY, ARCHITECTURE, THERMAL comfort, EVALUATION
Abstract

Optimal thermal performance of buildings is essential to ensure comfort, efficient energy management and environmental sustainability. In Australia, most building components and structures are designed according to criteria and prescriptive thermal design approaches derived from a steady state thermal model. A steady state thermal model is most precise when daily temperature fluctuations remain within a narrow range allowing for detail associated to large seasonal temperature variation. Due to the uniqueness of Australian climate, with potentially larger daily (smaller seasonal) temperature variations, a steady state approach can introduce significant errors when assessing building thermal performance. Herein, we analyze Australian weather data and evaluate both steady and transient state models parameters on case study Australian prefabricated building component systems. Mass-produced housing provides a unique opportunity to conduct this research. We develop a working methodology using analytic and numerical methods complemented by experimental thermal test data. Based on the prefabricated housing case proof-of-concept, this work proposes new prescriptive criteria for building design, which includes daily and seasonal temperature variations and tailors building component system design to its specific geographical locations. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

31. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.

Author

Gore, M.E., Griffin, C.L., Hancock, B., Patel, P.M., Pyle, L., Aitchison, M., James, N., Oliver, R.T.D., Mardiak, J., Hussain, T., Sylvester, R., Parmar, M.K., Royston, P., Mulders, P.F.A., Gore, M.E., Griffin, C.L., Hancock, B., Patel, P.M., Pyle, L., Aitchison, M., James, N., Oliver, R.T.D., Mardiak, J., Hussain, T., Sylvester, R., Parmar, M.K., Royston, P., and Mulders, P.F.A.

Abstract

Item does not contain fulltext, BACKGROUND: In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a. METHODS: RE04/30012 was an open-label randomised trial undertaken in 50 centres across eight countries. 1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non-stratified log-rank test. Analysis was by intention to treat. This study is registered, number ISRCTN 46518965. FINDINGS: 502 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment. Median follow-up was 37.2 months (24.8-52.3). Median overall survival was 18.8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for those receiving combination therapy. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90-1.21], p=0.55; absolute difference 0.3% (-5.1 to 5.6) at 1 year and 2.7% (-8.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving combined treatment. INTERPRETATION: Although combination therapy does not improve overall or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from immunotherapy is crucial. FUNDING: UK Medical Research Council.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results